ClinicalTrials.gg
RecruitingNCT04936009Updated Feb 9, 2026

Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)

An interventional study of Transcranial Magnetic Stimulation (TMS) in Autism Spectrum Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Autism Spectrum Disorder by Yale University — 3 open to participants now, 4 under way, none of them phase 3. Autism Spectrum Disorder · Yale University.

Planned enrollment
8th of 20
60 · median 40
Started
2022
with 1 other
No phase
18 of 24
3 open now
Registered
20th of 24
by date

Among the 24 studies in Autism Spectrum Disorder by Yale University, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 18 with no phase, and was the 20th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

3 of the 24 studies in Autism Spectrum Disorder by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Autism Spectrum Disorder by Yale University, or all of them as a file.
02

Study summary

This is a randomized interventional study designed to evaluate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition in adults with autism spectrum disorder (ASD).

Read the detailed description

The primary objective of this study is to determine whether rTMS increases the brain response to faces in a population of adults with ASD. This study will assess critical aspects of social cognition using the electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single rTMS session (or Sham) to provide preliminary insight into the potential of rTMS as a tool to modify social brain function in this population.

Participant visits will include a baseline assessment of neuropsychological, cognitive and behavioral function, and a pre and post TMS session with EEG (electroencephalogram) and eye-tracking to measure neural and visual attentional social response. Two study visits will be scheduled for each participant lasting approximately 4-5hrs total.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals between the ages of 18 and 40 years old with typical development or with a diagnosis of autism spectrum disorder.
  • Individuals able to participate in an EEG and eye-tracking experiment.

Exclusion criteria

Exclusion Criteria:

  • Participants reporting significant head trauma or serious brain illness.
  • Participants with major psychiatric illness that would preclude completion of study measures.
  • Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of seizures.
  • Participants taking prescription medications that may affect cognitive processes under study.
  • Participants who have taken alcohol or recreational drugs within the preceding 24 hours.
  • Females of known/suspected pregnancy or who test positive on a pregnancy test.
  • Participants with a history of metalworking or injury by shrapnel or metallic objects are also excluded.
  • Participants with a history of prior TMS therapy or use of an drug within 12 weeks of visit.
  • Participants with an IQ (intelligence quotient) below 80.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Transcranial Magnetic Stimulation - real

    Participants will receive active TMS during their study visit

    Behavioral: Transcranial Magnetic Stimulation (TMS)

  • Placebo comparator
    Transcranial Magnetic Stimulation - sham

    Participants will receive sham stimulation during their study visit simulating TMS

    Behavioral: Transcranial Magnetic Stimulation (TMS)

Interventions

  • BehavioralTranscranial Magnetic Stimulation (TMS)

    Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions

06

What researchers measure

Primary outcomes

  1. right hemisphere N170 latency

    EEG brain response to faces as measured by the N170 component in milliseconds

    Time frame: Measures will be recorded during the EEG/ET sessions of participant visits for an expected 1-2 hours

  2. proportion of visual attention to the eye region of the face

    visual attention to the eye region of the face as measured by eye tracking in seconds

    Time frame: Measures will be recorded during the EEG/ET sessions of participant visits for an expected 1-2 hours

07

Study locations

1 of 1 sites recruiting
  • Yale University Child Study Center
    New Haven, Connecticut 06520, United States
    Recruiting
    • Nicole Wright · Contactn.wright@yale.edu · 860-785-3488
    • Adam Naples, PhD · Sub investigator
    • James McPartland, PhD · Principal investigator
08

References and documents

Publications

  • Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. PubMed 19833552 ↗
  • Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005 Jan 20;45(2):201-6. doi: 10.1016/j.neuron.2004.12.033. PubMed 15664172 ↗
  • Allison T, Puce A, McCarthy G. Social perception from visual cues: role of the STS region. Trends Cogn Sci. 2000 Jul;4(7):267-278. doi: 10.1016/s1364-6613(00)01501-1. PubMed 10859571 ↗
  • McPartland J, Dawson G, Webb SJ, Panagiotides H, Carver LJ. Event-related brain potentials reveal anomalies in temporal processing of faces in autism spectrum disorder. J Child Psychol Psychiatry. 2004 Oct;45(7):1235-45. doi: 10.1111/j.1469-7610.2004.00318.x. PubMed 15335344 ↗
  • Dawson G, Toth K, Abbott R, Osterling J, Munson J, Estes A, Liaw J. Early social attention impairments in autism: social orienting, joint attention, and attention to distress. Dev Psychol. 2004 Mar;40(2):271-83. doi: 10.1037/0012-1649.40.2.271. PubMed 14979766 ↗
  • Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb;45(2):524-36. doi: 10.1007/s10803-013-1960-2. PubMed 24127165 ↗
  • Abujadi C, Croarkin PE, Bellini BB, Brentani H, Marcolin MA. Intermittent theta-burst transcranial magnetic stimulation for autism spectrum disorder: an open-label pilot study. Braz J Psychiatry. 2018 Jul-Sep;40(3):309-311. doi: 10.1590/1516-4446-2017-2279. Epub 2017 Dec 11. PubMed 29236921 ↗
  • Ni HC, Hung J, Wu CT, Wu YY, Chang CJ, Chen RS, Huang YZ. The Impact of Single Session Intermittent Theta-Burst Stimulation over the Dorsolateral Prefrontal Cortex and Posterior Superior Temporal Sulcus on Adults with Autism Spectrum Disorder. Front Neurosci. 2017 May 9;11:255. doi: 10.3389/fnins.2017.00255. eCollection 2017. PubMed 28536500 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 57 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2021
First posted
Jun 23, 2021
StartActual
Mar 17, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 1, 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04936009
Lead sponsor
Yale University
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Mar 17, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Nicole Wright, BS
Contact
n.wright@yale.edu
203-785-3488
Adam Naples, PhD
Contact
adam.naples@yale.edu
203-785-2583
James McPartland, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion